Sodium-glucose Cotransporter 2 Inhibitors and Cancer: a Systematic Review and Meta-Analysis

The effect of sodium–glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of various types of cancer. We used the Mantel–Haenszel method, fixed effects model, risk ratio (RR) and 95